Laws and Labels: A Regulatory View of Biosimilars

Friday, October 30, 2015
Presented by: 
Erika Lietzan

Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.

You may also like:

Blog Post

Any clinician that has a role in medication therapy is affected by allergen screening. Common scenarios in which potential allergen interactions would need to be considered include: A physician entering a new ...

View Blog Post
Blog Post

Two years ago, I wrote a blog about health information exchange (HIE) and the role of the pharmacist in this important co...

View Blog Post
Blog Post

As we approach the midyear point, it’s a great opportunity to benchmark several key trends that are challenging both the pharmacy business and profession and compare them to the

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up